Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine versus clarithromycin for persistent dyspnea and cough after acute COVID-19
IRCT20200718048129N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hydroxychloroquine and clarithromycin in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Dyspnea and Cough. Started Aug 2020; status: completed.
02
Drugs
hydroxychloroquineclarithromycin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200718048129N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200718048129N1.